Lonza names Siegfried Holding boss as new CEO
Enforcement Report - Week of December 20, 2023
Changes in Siegfried’s Executive Committee
Siegfried acquires majority stake in DiNAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies
Siegfried begins construction of a new global R&D Center for Drug Substances in Evionnaz
Siegfried increases distribution and ap­points new board member
Siegfried, a leading global Contract Development and Manufacturing Organization headquartered in Zofingen (Switzerland), inaugurates its new Development Center for Drug Products at its two Spanish sites in Barberà del Vallès and El Masnou near Barcelona (Spain). The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network.
In a year of macroeconomic uncertainties, Siegfried demonstrated its resilience and delivered a strong performance for the full year 2022. Net sales reached 1.229 billion Swiss francs (CHF), an increase of 15.6 percent in local currencies (2021: CHF 1.102 billion), supported by both, Drug Substances and Drug Products. Core EBITDA grew from CHF 207.2 million to now CHF 272.5 million, 31.5 percent higher than 2021. This resulted in a core EBITDA margin of 22.2 percent (2021: 18.8 percent), exceeding the 20 percent mark for the first time on a full2 year basis. Core net profit grew by 34.1 percent to CHF 127.8 million (2021: CHF 95.3 million). Net profit according to Swiss GAAP FER was higher than the core net profit and amounted to CHF 156.5 million. The Board of Directors will propose to the Annual General Meeting an increase of the payout to the shareholders to 3.40 Swiss francs per share (2021: CHF 3.20). As in the previous year, the payout will be made by reducing the nominal value of the shares by way of a capital reduction.
As part of its growth strategy, Siegfried is strengthening the executive leadership team and appoints Christian Dowdeswell as Chief Business Officer Drug Substances and member of the Executive Committee. The actual start date shall be communicated at a later point in time. While Christian Dowdeswell will take over as Chief Business Officer Drug Substances, Marianne Späne will continue to serve as Chief Business Officer for Siegfried's Drug Products business, which has recently experienced strong growth organically, including the COVID vaccines business, as well as through the acquisition of the two manufacturing sites from Novartis in Spain.
After 10 years on the Board of Directors of the Siegfried Group, Board member Colin Bond has decided not to stand for re-election at the company’s upcoming Annual General Meeting (AGM) on 20 April 2023.